This study was designed as a try to apply molecular, conventional cytogenetic, and immunological techniques as conformational diagnosis of bcr-abl gene and protein, and also to follow up chronic myeloid leukemia patients (CML) treated with imatinb mesylate (IM) for assessment of response at different IM treatment durations. Molecular screening for the presence of bcr-abl gene in 34 CML patients and negative controls were done using Multiplex-Single Step-Reverse Transcriptase-Polymerase Chain Reaction. The results showed that all CML patients were positive for bcr-abl gene while all the others were negative for this gene. For assessment of molecular response to IM, quantification of bcr-abl gene in CML patients were done using Real Time-Reverse Transcriptase-Polymerase Chain Reaction-Taqman.CML patients, who show signs of treatment non-response or relapse, were screened for T315I mutation using Allele Specific oligonucleotides. The results showed that this mutation dose not detected in any of those patients.In conclusion, obligatory complementary tests that should be performed for any CML patient who start to receive IM, in order to assess the full respons to therapy.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
This study was designed as a try to apply molecular, conventional cytogenetic, and immunological techniques as conformational diagnosis of bcr-abl gene and protein, and also to follow up chronic myeloid leukemia patients (CML) treated with imatinb mesylate (IM) for assessment of response at different IM treatment durations. Molecular screening for the presence of bcr-abl gene in 34 CML patients and negative controls were done using Multiplex-Single Step-Reverse Transcriptase-Polymerase Chain Reaction. The results showed that all CML patients were positive for bcr-abl gene while all the others were negative for this gene. For assessment of molecular response to IM, quantification of bcr-abl gene in CML patients were done using Real Time-Reverse Transcriptase-Polymerase Chain Reaction-Taqman.CML patients, who show signs of treatment non-response or relapse, were screened for T315I mutation using Allele Specific oligonucleotides. The results showed that this mutation dose not detected in any of those patients.In conclusion, obligatory complementary tests that should be performed for any CML patient who start to receive IM, in order to assess the full respons to therapy.
Name: Maysaa Abdul Razzaq Dhahi/ Nationality: Iraq/ Qualification: BSc in Microbiology-College of Science. MSc in Biotechnology (Molecular Biology),College of Science- Baghdad University. PhD in Microbiology(Molecular Biology),College of Medicine, Al-Nahrain University
Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
Taschenbuch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This study was designed as a try to apply molecular, conventional cytogenetic, and immunological techniques as conformational diagnosis of bcr-abl gene and protein, and also to follow up chronic myeloid leukemia patients (CML) treated with imatinb mesylate (IM) for assessment of response at different IM treatment durations. Molecular screening for the presence of bcr-abl gene in 34 CML patients and negative controls were done using Multiplex-Single Step-Reverse Transcriptase-Polymerase Chain Reaction. The results showed that all CML patients were positive for bcr-abl gene while all the others were negative for this gene. For assessment of molecular response to IM, quantification of bcr-abl gene in CML patients were done using Real Time-Reverse Transcriptase-Polymerase Chain Reaction-Taqman.CML patients, who show signs of treatment non-response or relapse, were screened for T315I mutation using Allele Specific oligonucleotides. The results showed that this mutation dose not detected in any of those patients.In conclusion, obligatory complementary tests that should be performed for any CML patient who start to receive IM, in order to assess the full respons to therapy. 220 pp. Englisch. N° de réf. du vendeur 9783659202926
Quantité disponible : 2 disponible(s)
Vendeur : moluna, Greven, Allemagne
Etat : New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Autor/Autorin: Dhahi Maysaa A. R.Name: Maysaa Abdul Razzaq Dhahi/ Nationality: Iraq/ Qualification: BSc in Microbiology-College of Science. MSc in Biotechnology (Molecular Biology),College of Science- Baghdad University. PhD in Microbiology. N° de réf. du vendeur 5139320
Quantité disponible : Plus de 20 disponibles
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Taschenbuch. Etat : Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - This study was designed as a try to apply molecular, conventional cytogenetic, and immunological techniques as conformational diagnosis of bcr-abl gene and protein, and also to follow up chronic myeloid leukemia patients (CML) treated with imatinb mesylate (IM) for assessment of response at different IM treatment durations. Molecular screening for the presence of bcr-abl gene in 34 CML patients and negative controls were done using Multiplex-Single Step-Reverse Transcriptase-Polymerase Chain Reaction. The results showed that all CML patients were positive for bcr-abl gene while all the others were negative for this gene. For assessment of molecular response to IM, quantification of bcr-abl gene in CML patients were done using Real Time-Reverse Transcriptase-Polymerase Chain Reaction-Taqman.CML patients, who show signs of treatment non-response or relapse, were screened for T315I mutation using Allele Specific oligonucleotides. The results showed that this mutation dose not detected in any of those patients.In conclusion, obligatory complementary tests that should be performed for any CML patient who start to receive IM, in order to assess the full respons to therapy. N° de réf. du vendeur 9783659202926
Quantité disponible : 1 disponible(s)
Vendeur : Books Puddle, Woodside, NY, Etats-Unis
Etat : New. pp. 220. N° de réf. du vendeur 26128783445
Quantité disponible : 4 disponible(s)
Vendeur : Majestic Books, Hounslow, Royaume-Uni
Etat : New. Print on Demand pp. 220 2:B&W 6 x 9 in or 229 x 152 mm Perfect Bound on Creme w/Gloss Lam. N° de réf. du vendeur 131771274
Quantité disponible : 4 disponible(s)
Vendeur : Biblios, Frankfurt am main, HESSE, Allemagne
Etat : New. PRINT ON DEMAND pp. 220. N° de réf. du vendeur 18128783455
Quantité disponible : 4 disponible(s)
Vendeur : Mispah books, Redhill, SURRE, Royaume-Uni
Paperback. Etat : Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book. N° de réf. du vendeur ERICA75836592029245
Quantité disponible : 1 disponible(s)
Vendeur : buchversandmimpf2000, Emtmannsberg, BAYE, Allemagne
Taschenbuch. Etat : Neu. This item is printed on demand - Print on Demand Titel. Neuware -This study was designed as a try to apply molecular, conventional cytogenetic, and immunological techniques as conformational diagnosis of bcr-abl gene and protein, and also to follow up chronic myeloid leukemia patients (CML) treated with imatinb mesylate (IM) for assessment of response at different IM treatment durations. Molecular screening for the presence of bcr-abl gene in 34 CML patients and negative controls were done using Multiplex-Single Step-Reverse Transcriptase-Polymerase Chain Reaction. The results showed that all CML patients were positive for bcr-abl gene while all the others were negative for this gene. For assessment of molecular response to IM, quantification of bcr-abl gene in CML patients were done using Real Time-Reverse Transcriptase-Polymerase Chain Reaction-Taqman.CML patients, who show signs of treatment non-response or relapse, were screened for T315I mutation using Allele Specific oligonucleotides. The results showed that this mutation dose not detected in any of those patients.In conclusion, obligatory complementary tests that should be performed for any CML patient who start to receive IM, in order to assess the full respons to therapy.OmniScriptum SRL, Str. Armeneasca 28/1, office 1, 2012 Chisinau 220 pp. Englisch. N° de réf. du vendeur 9783659202926
Quantité disponible : 1 disponible(s)
Vendeur : preigu, Osnabrück, Allemagne
Taschenbuch. Etat : Neu. Molecular Detection and Quantification of BCR-ABL gene | Molecular detection | Maysaa A. R. Dhahi | Taschenbuch | 220 S. | Englisch | 2012 | LAP LAMBERT Academic Publishing | EAN 9783659202926 | Verantwortliche Person für die EU: preigu GmbH & Co. KG, Lengericher Landstr. 19, 49078 Osnabrück, mail[at]preigu[dot]de | Anbieter: preigu. N° de réf. du vendeur 106165034
Quantité disponible : 5 disponible(s)